Home
Off-the-shelf
Humanized mice (target-specific)
genO-hCD47/hSIRPα
Humanized mice (target-specific)

Preclinical double-humanized genO‑hCD47/hSIRPα model

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

‍

‍

Contact Us

Applications of the genO‑hCD47/hSIRPα mouse model

Useful applications for researchers working in different biomedical fields, such as immuno-oncology, inflammation and autoimmunity:

  • Assess the efficacy of CD47- and/or SIRPα-targeting therapeutics
    • Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
  • Evaluate the safety and toxicity of compounds
  • Analyze the biodistribution of CD47- and/or SIRPα-targeting compounds
  • Investigate the mode of action (MoA) of CD47- and/or SIRPα-targeting compounds and understand their therapeutic potential

‍

Features

  • Expression of different human CD47 and human SIRPα isoforms
  • Physiological regulation and expression patterns of the human CD47 and human SIRPα
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target genes, thus avoiding cross-reactivity

Clients

University of Tübingen

Scientific articleScientific articlePosterPoster

Caedo Oncology

Scientific articleScientific articlePosterPoster

Related resources and publications

CD137

pulmonary embolism (PE)

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PosterS
(
0
)
Scientific Articles
(
0
)
CommentarIes
(
0
)
Case studies
(
0
)
No results
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Front Immunol

Dec 2023
Highlighted article
read the comment
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
No results
No results

Validation data

Discover related products to

genO-hCD47/hSIRPα

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Immune checkpoint
CTLA-4
ICP (single-target)

genO-hCTLA‑4

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

genO-hCTLA‑4/hLAG3

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD‑1/hCTLA‑4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD‑1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD‑1/hPD‑L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

genO-hPD‑1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

genO-hPD‑1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

CD137
ICP (single-target)
Immune checkpoint

genO‑hCD137

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

‍

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

genO‑hCD28

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

genO‑hGITR

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

genO‑hGITR/hGITRL

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

MC38
Immune checkpoint
PD-L1
CD47

genO-MC38-hPD‑L1-hCD47-LZ

The genO‑MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

Preclinical double-humanized genO‑hCD47/hSIRPα model

Get in touch about

Let us know how we can help